p21 (CDKN1A) Mouse Monoclonal Antibody [Clone ID: OTI7C8]

SKU TA808164

CDKN1A mouse monoclonal antibody, clone OTI7C8 (formerly 7C8)

Product Data

• Clone Name: OTI7C8
• Application: IHC, WB
• Recommended Dilution: WB 1:2000, IHC 1:150
• Reactivity: Human
• Antibody Host: Mouse
• Isotype: IgG2b
• Clonality: Monoclonal
• Immunogen: Human recombinant protein fragment corresponding to amino acids 2-164 of human CDKN1A(NP_510867) produced in E.coli.
• Buffer: PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.
• Concentration: 1 mg/ml
• Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
• Conjugation: Unconjugated
• Storage: Store at -20°C as received.
• Stability: Stable for 12 months from date of receipt.
• Shipping: Blue Ice
• Predicted Protein Size: 17.9 kDa
• Gene Name: cyclin-dependent kinase inhibitor 1A
• Database Link:
  NP_510867
  P38936
• Background: This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Multiple alternatively spliced variants have been found for this gene. [provided by RefSeq, Nov 2010]
• Synonyms: CAP20; CDKN1; CIP1; MDA-6; P21; p21CIP1; SDI1; WAF1

Reference Data

• Protein Families: Druggable Genome
• Protein Pathways: Bladder cancer, Cell cycle, Chronic myeloid leukemia, ErbB signaling pathway, Glioma, Melanoma, p53 signaling pathway, Pathways in cancer, Prostate cancer